<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:02:28Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5052303" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5052303</identifier><datestamp>2016-10-20</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Genet</journal-id>
      <journal-title-group>
        <journal-title>Human Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0340-6717</issn>
      <issn pub-type="epub">1432-1203</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5052303</article-id>
      <article-id pub-id-type="pmcid">PMC5052303</article-id>
      <article-id pub-id-type="pmc-uid">5052303</article-id>
      <article-id pub-id-type="pmid">27481395</article-id>
      <article-id pub-id-type="publisher-id">1719</article-id>
      <article-id pub-id-type="doi">10.1007/s00439-016-1719-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Investigation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9427-7240</contrib-id>
          <name>
            <surname>Alfadhel</surname>
            <given-names>Majid</given-names>
          </name>
          <address>
            <phone>+966 118 011 111</phone>
            <email>dralfadhelm@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nashabat</surname>
            <given-names>Marwan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Qahtani</surname>
            <given-names>Hanan Al</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alfares</surname>
            <given-names>Ahmed</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mutairi</surname>
            <given-names>Fuad Al</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shaalan</surname>
            <given-names>Hesham Al</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Douglas</surname>
            <given-names>Ganka V.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wierenga</surname>
            <given-names>Klaas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Juusola</surname>
            <given-names>Jane</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alrifai</surname>
            <given-names>Muhammad Talal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arold</surname>
            <given-names>Stefan T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alkuraya</surname>
            <given-names>Fowzan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ali</surname>
            <given-names>Qais Abu</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Division of Genetics, Department of Pediatrics, King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs (NGHA), King Abdulaziz Medical City, PO Box 22490, Riyadh, 11426 Saudi Arabia </aff>
        <aff id="Aff2"><label>2</label>Medical Imaging Department, King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs (NGHA), King Abdulaziz Medical City, Riyadh, Saudi Arabia </aff>
        <aff id="Aff3"><label>3</label>Department of Pediatrics, College of Medicine, Qassim University, Almulyda, Saudi Arabia </aff>
        <aff id="Aff4"><label>4</label>GeneDx, Gaithersburg, MD 20877 USA </aff>
        <aff id="Aff5"><label>5</label>Department of Pediatrics, Section of Genetics, The University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK USA </aff>
        <aff id="Aff6"><label>6</label>Neurology Division, Department of Pediatrics, King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs (NGHA), King Abdulaziz Medical City, Riyadh, Saudi Arabia </aff>
        <aff id="Aff7"><label>7</label>Division of Biological and Environmental Sciences and Engineering (BESE), Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900 Saudi Arabia </aff>
        <aff id="Aff8"><label>8</label>Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia </aff>
        <aff id="Aff9"><label>9</label>Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>1</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2016</year>
      </pub-date>
      <volume>135</volume>
      <issue>11</issue>
      <fpage>1263</fpage>
      <lpage>1268</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>6</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>7</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Glycine cleavage system (GCS) catalyzes the degradation of glycine and disruption of its components encoded by <italic>GLDC</italic>, <italic>AMT</italic> and <italic>GCSH</italic> are the only known causes of glycine encephalopathy, also known as non-ketotic hyperglycinemia (NKH). In this report, we describe a consanguineous family with one child who presented with NKH, but harbored no pathogenic variants in any of the three genes linked to this condition. Whole-exome sequencing revealed a novel homozygous missense variant in exon 9 of <italic>SLC6A9</italic> NM_201649.3: c.1219 A&gt;G (p.Ser407Gly) that segregates with the disease within the family. This variant replaces the highly conserved S407 in the ion-binding site of this glycine transporter and is predicted to disrupt its function. In murine model, knockout of <italic>Slc6a9</italic> is associated with equivalent phenotype of NKH, namely respiratory distress and hypotonia. This is the first demonstration that mutation of the glycine transporter can be associated with NKH in humans.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© Springer-Verlag Berlin Heidelberg 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Although glycine is the smallest amino acid, it is considered a conditionally essential amino acid, as de novo synthesis may not be sufficient (Wang et al. <xref ref-type="bibr" rid="CR18">2013</xref>). It is essential for various processes in the body, including protein, glutathione, creatine, purine, heme, and serine synthesis (Dai et al. <xref ref-type="bibr" rid="CR7">2013</xref>; Hall <xref ref-type="bibr" rid="CR13">1998</xref>). It is also essential for bile acid conjugation (Hafkenscheid and Hectors <xref ref-type="bibr" rid="CR12">1975</xref>), as well as playing an important role in immune modulation through the glycine-gated chloride channels (Zhong et al. <xref ref-type="bibr" rid="CR20">2003</xref>). Moreover, glycine acts as an inhibitory neurotransmitter in central nervous system (CNS) by hyperpolarizing the post-synaptic glycinergic neurons (Legendre <xref ref-type="bibr" rid="CR14">2001</xref>). Glycine levels are controlled by two main mechanisms; first, glycine degradation, mainly by the Glycine Cleavage System (GCS) and to a lesser extent formation of serine (Wang et al. <xref ref-type="bibr" rid="CR18">2013</xref>), and second, by glycine transport system which is mediated by two sodium-dependent carriers, mainly GLYT1 and GLYT2. Glycine Transporter 1 (GlyT1) balances the extracellular glycine concentration predominantly in CNS (Betz et al. <xref ref-type="bibr" rid="CR5">2006</xref>).</p>
      <p>Disruption of the GCS leads to glycine encephalopathy or non-ketotic hyperglycinemia (NKH), where CSF-to-plasma glycine ratio is elevated. In utero, fetal hiccups and myoclonus might be noticed, which may persist after delivery in addition to hypotonia and respiratory disturbances. Later, in life, patients develop seizures and intellectual disability (Dalla Bernardina et al. <xref ref-type="bibr" rid="CR8">1979</xref>). Nearly all cases of NKH have been found to harbor disease-causing autosomal recessive variants in the genes encoding the different components of the GCS: glycine decarboxylase (<italic>GLDC</italic>), which encodes P protein, aminomethyltransferase gene (<italic>AMT</italic>), which encodes T protein; and glycine cleavage system H gene (<italic>GCSH</italic>), which encodes H protein (Applegarth and Toone <xref ref-type="bibr" rid="CR2">2006</xref>).</p>
      <p>Glycine encephalopathy caused by glycine transporter system was proposed as a distinct entity only once in an atypical NKH case. Mayor et al. (<xref ref-type="bibr" rid="CR15">1984</xref>) described a patient who presented with classic symptoms of NKH; however, no confirmatory mutation analysis was conducted (Mayor et al. <xref ref-type="bibr" rid="CR15">1984</xref>). In this study, we suggest that NKH can, indeed, be caused by mutation of the glycine transporter, which we suggest is a novel, albeit rare cause of NKH in humans.</p>
    </sec>
    <sec id="Sec2">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Human subjects</title>
        <p>The index case underwent full clinical evaluation by a clinical geneticist for her multisystem disorder (see below). Standard clinical-exome consent was obtained from the probandâs parents. Blood samples were collected from index case and parents in EDTA tubes for DNA extraction, and trio whole-exome sequencing analysis (proband and both parents) was performed at a CLIA-certified clinical diagnostic laboratory.</p>
      </sec>
      <sec id="Sec4">
        <title>Exome analysis</title>
        <p>Genomic DNA was extracted from whole blood for the affected proband and family members (both unaffected parents and unaffected sister). Exome sequencing at GeneDx was performed on exon targets isolated by capture using the Agilent Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). The sequencing methodology and variant interpretation protocol have been previously described (Tanaka et al. <xref ref-type="bibr" rid="CR17">2015</xref>). The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/">http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/</ext-link>).</p>
        <p>Percent covered at 10Ã for the proband was 96.37, while that for mother and father was 96.22 and 96.42, respectively. Mean coverage for the proband was 132.67, while that for mother and father was 116.72 and 130.07, respectively. Sanger sequencing of <italic>AMT</italic>, <italic>GLDC</italic>, and <italic>GCSH,</italic> which are mutated in NKH, was performed to further rule out mutation of any of these genes as the cause of the patientâs phenotype.</p>
      </sec>
      <sec id="Sec5">
        <title>Computational structural analysis of mutants</title>
        <p>Sequences were retrieved from the Uniprot database. BLAST and SwissModel (Arnold et al. <xref ref-type="bibr" rid="CR3">2006</xref>) were used to search for suitable structural templates in the Protein Data Bank (PDB). SwissModel was used to produce homology models. Models were manually inspected and evaluated using the Pymol program (pymol.org).</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <sec id="Sec7">
        <title>Clinical report</title>
        <p>The index case is a 15-month-old girl product of full-term pregnancy via normal spontaneous vaginal delivery, born to first cousin Saudi parents 
(Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). Pregnancy was complicated by polyhydramnios, and there was no history of abnormal fetal movements. Maternal obstetric history was significant for two first trimester miscarriages and a healthy older daughter (G4P2Â +Â 2) with the same partner. Birth growth parameters include weight 2900Â g (â0.8 SD), length 50Â cm (0.45 SD), and OFC 34.5Â cm (0.52 SD). Shortly, after birth, she developed shallow breathing and acute respiratory distress that required intubation and ventilatory support for 1Â month prior to successful extubation in the NICU. Neonatal course, starting at age of 3Â days, was further complicated by seizure-like episodes, which were medically controlled with phenobarbital and phenytoin. Subsequently, it was noted that these symptoms were likely exaggerated startle reflexes provoked by sudden loud sounds and tactile stimulation, i.e., hyperekplexia. All antiepileptic medications were gradually tapered, as such seizure-like episodes and startle reflexes improved over time and completely subsided by age 6Â months. In addition, the patient had hypotonia, weak cry, difficulty swallowing which lead to aspiration, multiple hospitalizations, and eventually insertion of gastrostomy tube. Clinical follow-up at 15Â months of age showed failure to thrive and microcephaly: weight was 6.8Â kg (â2.8 SD), length 73Â cm (â1.6 SD), and head circumference 40.5Â cm (â3.7 SD). Subtle facial dysmorphic features were noted: microcephaly, broad forehead, esotropia, low set ears, retrognathia, deep prominent philtrum, and sparse eyebrows (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). Developmentally, she had global delay, including motor and speech. Neurological examination showed central hypotonia with brisk deep tendon reflexes peripherally; musculoskeletal examination showed bilateral joint laxity around the elbows with bilateral club feet. Rest of clinical exam was unremarkable. The following laboratory investigations were unremarkable: newborn screening, CBC, renal function, liver function, ammonia, serum lactic acid, urine organic acids, chromosomal analysis, CGH microarray, and clinical sequencing of <italic>AMT</italic>, <italic>GLDC</italic>, and <italic>GCSH</italic> genes.<fig id="Fig1"><label>Fig.Â 1</label><caption><p>
<bold>a</bold> Family pedigree, <bold>b</bold> esotropia and microcephaly, broad forehead, esotropia, low set ears, retrognathia, deep prominent philtrum and sparse eyebrows, <bold>c</bold> selected MR image of the brain at the level of basal ganglia, coronal T2-WI shows bilateral subinsular white matter hyper intensity (<italic>arrows</italic>) and right head of caudate atrophy with a tiny cyst (<italic>star</italic>), <bold>d</bold> axial T2-WI shows bilateral scattered subcortical and periventricular white matter hyperintensities (<italic>arrows</italic>)</p></caption><graphic xlink:href="439_2016_1719_Fig1_HTML" id="MO1"/></fig>
</p>
        <p>Plasma amino acids showed mild elevation of glycine at 288Â Âµmol/L (normal: 73â241). Urine amino acids also showed mild elevation of glycine at 393Â ÂµM/mM Cr (normal: 110â356), methionine at 66Â ÂµM/mM Cr (normal: 7â29), ethanolamine at 98Â ÂµM/mM Cr (normal: not detected), and ornithine at 14Â ÂµM/mM Cr (normal:Â &lt;8). This prompted CSF amino acid analysis, which revealed elevated glycine at 21Â Âµmol/L (normal: 2.2â14.2) and CSF/plasma glycine ratio, was elevated at 0.07(normal:Â &lt;0.02). Electroencephalogram (EEG) and echocardiogram were both normal. Skeletal survey showed right developmental dysplasia of the hip (DDH), superior dislocation of the right proximal femur, and bilateral club feet. Magnetic resonance imaging (MRI) of the brain showed bilateral subinsular white matter T2 hyperintensity, right head of caudate atrophy with tiny cyst, and bilateral scattered subcortical and periventricular white matter changes (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>).
</p>
        <p>Whole-exome sequencing showed a novel homozygous missense variant in exon 9 of the <italic>SLC6A9</italic> gene: NM_201649.3: c.1219 A&gt;G (p.Ser407Gly), as both parents and the older sister were heterozygous for this variant. This missense variant has not previously been reported in any of the publicly available population catalogs (1000 Genomes, NHLBI ESP/EVS, ExAC),Â &gt;1400 individuals of Arabic background in GeneDx internal exome database, or 2000 ethnically matched (Saudi) exomes from the Saudi Human Genome Program database. Moreover, the discovered variant resides within the autozygome. This missense change is predicted to be pathogenic by various in silico models: SIFT (0.003), PolyPhen (1) and CADD (26.9).</p>
        <p>The SLC6A9 protein can be modelled based on the crystal structure of the 46Â % identical dopamine transporter (PDB accession 4xpa and related entries) from Drosophila, or the 43Â % identical human sodium-dependent serotonin transporter (PDB 5i6z). In both these template sequences and structures, the serine at position 407 is conserved. Ser407 is located in the middle of transmembrane helix 7. Although it is not in direct contact with the ligand channel, and positioned in a distance of about 7â10Â Ã to the ligand, Ser407 contributes to a cavity that binds a chloride and sodium ion in the highly similar dopamine transporter (Wang et al. <xref ref-type="bibr" rid="CR19">2015</xref>) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>). This ion-binding site allows the receptor to correlate substrate transport with pre-existing chloride and sodium gradients. The ion-binding site is strictly conserved between the Drosophila dopamine receptor and human SLC6A9. S407G is a non-conservative replacement, where the small and hydrophilic Ser is replaced by a more flexible more hydrophobic glycine without any side chain. This replacement changes the shape and chemical properties of the ion-binding site and, hence, disrupts normal functioning of the transporter.<fig id="Fig2"><label>Fig.Â 2</label><caption><p>3D homology model of human SLC6A9, based on the dopamine transporter (PDB 4xpa). The dopamine analogue 3,4-dichlorophenethylamine (<italic>yellow</italic>), sodium (<italic>magenta</italic>), and chloride (<italic>cyan</italic>) ions have been taken over from the dopamine receptor structure that served as template. The bound ions are expected to be located in the wild-type (but not the S406 mutant) SLC6A9, as they are in the dopamine transporter, because of strict conservation of the ion-binding site. However, the dopamine analogue is of course replaced by glycine in SLC6A9, and the dopamine analogue is only displayed to illustrate the location of S406 with respect to the ligand molecule</p></caption><graphic xlink:href="439_2016_1719_Fig2_HTML" id="MO2"/></fig>
</p>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Discussion</title>
      <p>In this report, we present the first case in the literature of presumptive glycine transporter defect in association with a novel variant in <italic>SLC6A9</italic>. Solute Carrier Family 6 (SLC6), also known as neurotransmitters transporters or Na+/Clâ dependent transporter family, is a group of transporters for neurotransmitters, proteinogenic amino acids, betaine, taurine, and creatine. SLC6 is further subdivided into four subfamilies; monoamine transporters (SLC6A2, SLC6A3, and SLC6A4), GABA transporters (SLC6A1, SLC6A13, and SLC6A11), glycine transporters (SLC6A9, SLC6A5, SLC6A14, and SLC6A7), and neutral amino acid transporter (SLC6A19, SLC6A15, and SLC6A18) (Alexander et al. <xref ref-type="bibr" rid="CR1">2015</xref>).</p>
      <p>
<italic>SLC6A9</italic> encodes GlyT1, which is located in the plasma membrane, predominantly in glial cells and neurons. Its main function is to modulate glycine level in the synapse by transporting glycine from the synaptic cleft into cells. Various experiments showed evidence of crucial role of GlyT1 in the development of basic respiratory pattern and tone as GlyT1 deficiency (<italic>Slc6a9</italic> knockout) in mice causes severe respiratory distress and death shortly after birth (Chalphin and Saha <xref ref-type="bibr" rid="CR6">2010</xref>; Gomeza et al. <xref ref-type="bibr" rid="CR11">2003</xref>), which faithfully recapitulates our patientâs acute respiratory distress postnatally.</p>
      <p>Mayor et al. (<xref ref-type="bibr" rid="CR15">1984</xref>) case presented with typical NKH symptoms, however, GCS functional study was normal. Furthermore, the glycine transport system was absent in brain autopsy, but no confirmatory mutation analysis was conducted (Mayor et al. <xref ref-type="bibr" rid="CR15">1984</xref>).</p>
      <p>The presented patient shared similarities with other NKH patients, regarding the age of onset and various clinical features, such as hypotonia, early respiratory distress, myoclonic jerks, and seizures (TableÂ <xref rid="Tab1" ref-type="table">1</xref>), although she also exhibited subtle facial dysmorphic features that have not been described in patients with NKH. More importantly, burst suppression pattern on EEG, which is commonly observed in classical NKH, was not observed in this patient as EEG was reportedly normal. In addition, biochemical profile showed elevation of CSF/plasma glycine ratio (0.07), in contrast to classic NKH patients, where CSF/plasma glycine ratio is usually greater than 0.08. We also note that the probandâs exaggerated startle reflex during the first 6Â months of age (hyperekplexia), has previously been reported as a feature in association with <italic>SLC6A5</italic>-related disorders (Arribas-Gonzalez et al. <xref ref-type="bibr" rid="CR4">2015</xref>; Dreissen and Tijssen <xref ref-type="bibr" rid="CR10">2012</xref>; Michael Davis et al. <xref ref-type="bibr" rid="CR9">1993</xref>; Supplisson and Roux <xref ref-type="bibr" rid="CR16">2002</xref>), but not in association with NKH, suggesting this feature might be a common finding between GlyT1 and GlyT2 systems. Another possible explanation for the startle reflex could be due to the excitatory effect of glycine on the glutamatergic neurons through <italic>N</italic>-methyl-<sc>d</sc>-aspartic acid (NMDA) receptors, leading to depolarization of the post-synaptic neurons (Betz et al. <xref ref-type="bibr" rid="CR5">2006</xref>), even though such symptoms subsided after 6Â months of age.<table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>Comparison between NKH and glycine transporter 1 defect</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Feature</th><th align="left">NKH</th><th align="left">GlyT1 variant</th></tr></thead><tbody><tr><td align="left">Age of onset</td><td align="left">Neonatal or infantile</td><td align="left">Neonatal</td></tr><tr><td align="left">Major clinical features</td><td align="left">Respiratory distress requiring mechanical ventilation, seizure, hypotonia, microcephaly, spastic quadriplegia, global developmental delay</td><td align="left">Respiratory distress requiring mechanical ventilation, microcephaly hypotonia, joint laxity, exaggerated startle response, developmental dysplasia of the hip, global developmental delay</td></tr><tr><td align="left">Facial dysmorphic features</td><td align="left">None</td><td align="left">Broad forehead, esotropia, low set ears, retrognathia, deep prominent philtrum, and sparse eyebrows</td></tr><tr><td align="left">Encephalopathy</td><td align="left">Present</td><td align="left">Absent</td></tr><tr><td align="left">Laboratory finding</td><td align="left">High CSF, plasma, and urine glycine</td><td align="left">High CSF, plasma, and urine glycine</td></tr><tr><td align="left">MRI</td><td align="left">Delayed myelination, absent corpus callosum, brain atrophy, and dilatation of the ventricles. White matter changes</td><td align="left">Atrophy in the caudate nucleus, white matter changes. Normal myelination.</td></tr><tr><td align="left">EEG</td><td align="left">Burst suppression pattern</td><td align="left">Normal</td></tr></tbody></table></table-wrap>
</p>
      <p>Long-term outcome for mice carrying heterozygous variants in GlyT1 has previously been documented (Gomeza et al. <xref ref-type="bibr" rid="CR11">2003</xref>); however, mice carrying homozygous variants expired soon postnatally, rendering it very difficult to predict natural history from structural, developmental, and behavioral aspects. Hypomorphic mutants will potentially clarify the full phenotypic consequences of GlyT1 deficiency in mouse to model what we observed in our human patient and we hope the reported variant can aid in the design of an appropriate knock-in strategy.</p>
      <p>In summary, we report the first living human case carrying a homozygous missense variant in <italic>SLC6A9</italic> and the associated phenotype includes: global developmental delay, hypotonia, subtle dysmorphic features, joint laxity, and clubfeet; high plasma and CSF glycine levels with elevated CSF-to-plasma glycine ratio; and brain white matter changes. However, we acknowledge that the disease link we propose in this study is based on a single patient. Further research and additional reports of <italic>SLC6A9</italic> variants are needed to elucidate the full <italic>SLC6A9</italic>-related phenotype and genotype spectrum in humans. In addition, as further delineation of various gene-related phenotypes and identification of more novel genes continue, future reanalysis of whole-exome sequencing data could help clarify if reported dysmorphic features are possibly associated with yet-to-be fully described genes.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We wish to thank the family of the patient for their enthusiastic participation. The research by STA reported in this publication was supported by funding from the King Abdullah University of Science and Technology (KAUST).</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
      <sec id="FPar2">
        <title>Funding statement</title>
        <p>This research received no funding grant from public, commercial or not-for-profit sectors.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>SP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Concise Guide to PHARMACOLOGY 2015/16: Transporters</article-title>
          <source>Br J Pharmacol</source>
          <year>2015</year>
          <volume>172</volume>
          <fpage>6110</fpage>
          <lpage>6202</lpage>
          <pub-id pub-id-type="doi">10.1111/bph.13355</pub-id>
          <?supplied-pmid 26650446?>
          <pub-id pub-id-type="pmid">26650446</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Applegarth</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Toone</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Glycine encephalopathy (nonketotic hyperglycinemia): comments and speculations</article-title>
          <source>Am J Med Genet A</source>
          <year>2006</year>
          <volume>140</volume>
          <fpage>186</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.31030</pub-id>
          <?supplied-pmid 16353254?>
          <pub-id pub-id-type="pmid">16353254</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnold</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bordoli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kopp</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwede</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling</article-title>
          <source>Bioinformatics</source>
          <year>2006</year>
          <volume>22</volume>
          <fpage>195</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/bti770</pub-id>
          <?supplied-pmid 16301204?>
          <pub-id pub-id-type="pmid">16301204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arribas-Gonzalez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>de Juan-Sanz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aragon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lopez-Corcuera</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of the dominant negative effect of a glycine transporter 2 mutation associated with hyperekplexia</article-title>
          <source>J Biol Chem</source>
          <year>2015</year>
          <volume>290</volume>
          <fpage>2150</fpage>
          <lpage>2165</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M114.587055</pub-id>
          <?supplied-pmid 25480793?>
          <pub-id pub-id-type="pmid">25480793</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Betz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gomeza</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Armsen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Scholze</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Eulenburg</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>Glycine transporters: essential regulators of synaptic transmission</article-title>
          <source>Biochem Soc Trans</source>
          <year>2006</year>
          <volume>34</volume>
          <fpage>55</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1042/BST0340055</pub-id>
          <?supplied-pmid 16417482?>
          <pub-id pub-id-type="pmid">16417482</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chalphin</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Saha</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>The specification of glycinergic neurons and the role of glycinergic transmission in development</article-title>
          <source>Front Mol Neurosci</source>
          <year>2010</year>
          <volume>3</volume>
          <fpage>11</fpage>
          <?supplied-pmid 20461146?>
          <pub-id pub-id-type="pmid">20461146</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dai</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nitric oxide and energy metabolism in mammals</article-title>
          <source>BioFactors</source>
          <year>2013</year>
          <volume>39</volume>
          <fpage>383</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="doi">10.1002/biof.1099</pub-id>
          <?supplied-pmid 23553707?>
          <pub-id pub-id-type="pmid">23553707</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dalla Bernardina</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aicardi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>GoutiÃ¨res</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Plouin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Glycine encephalopathy</article-title>
          <source>Neuropadiatrie</source>
          <year>1979</year>
          <volume>10</volume>
          <fpage>209</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0028-1085326</pub-id>
          <?supplied-pmid 583064?>
          <pub-id pub-id-type="pmid">583064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>Michael</given-names>
            </name>
            <name>
              <surname>Falls</surname>
              <given-names>William A</given-names>
            </name>
            <name>
              <surname>Campeau</surname>
              <given-names>Serge</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fear-potentiated startle: a neural and pharmacological analysis</article-title>
          <source>Behav Brain Res</source>
          <year>1993</year>
          <volume>58</volume>
          <fpage>175</fpage>
          <lpage>198</lpage>
          <pub-id pub-id-type="doi">10.1016/0166-4328(93)90102-V</pub-id>
          <?supplied-pmid 8136044?>
          <pub-id pub-id-type="pmid">8136044</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dreissen</surname>
              <given-names>YE</given-names>
            </name>
            <name>
              <surname>Tijssen</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>The startle syndromes: physiology and treatment</article-title>
          <source>Epilepsia</source>
          <year>2012</year>
          <volume>53</volume>
          <issue>Suppl 7</issue>
          <fpage>3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03709.x</pub-id>
          <?supplied-pmid 23153204?>
          <pub-id pub-id-type="pmid">23153204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomeza</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hulsmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Eulenburg</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Szoke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition</article-title>
          <source>Neuron</source>
          <year>2003</year>
          <volume>40</volume>
          <fpage>785</fpage>
          <lpage>796</lpage>
          <pub-id pub-id-type="doi">10.1016/S0896-6273(03)00672-X</pub-id>
          <?supplied-pmid 14622582?>
          <pub-id pub-id-type="pmid">14622582</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hafkenscheid</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Hectors</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>An enzymic method for the determination of the glycine/taurine ratio of conjugated bile acids in bile</article-title>
          <source>Clin Chim Acta</source>
          <year>1975</year>
          <volume>65</volume>
          <fpage>67</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1016/0009-8981(75)90335-6</pub-id>
          <?supplied-pmid 1238179?>
          <pub-id pub-id-type="pmid">1238179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Glycine</article-title>
          <source>J Parenter Enter Nutr</source>
          <year>1998</year>
          <volume>22</volume>
          <fpage>393</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="doi">10.1177/0148607198022006393</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Legendre</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The glycinergic inhibitory synapse</article-title>
          <source>Cell Mol Life Sci CMLS</source>
          <year>2001</year>
          <volume>58</volume>
          <fpage>760</fpage>
          <lpage>793</lpage>
          <pub-id pub-id-type="doi">10.1007/PL00000899</pub-id>
          <?supplied-pmid 11437237?>
          <pub-id pub-id-type="pmid">11437237</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayor</surname>
              <given-names>F</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rodriguez-Pombo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Benavides</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ugarte</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Atypical nonketotic hyperglycinemia with a defective glycine transport system in nervous tissue</article-title>
          <source>Neurochem Pathol</source>
          <year>1984</year>
          <volume>2</volume>
          <fpage>233</fpage>
          <lpage>249</lpage>
          <?supplied-pmid 6537469?>
          <pub-id pub-id-type="pmid">6537469</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Supplisson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roux</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Why glycine transporters have different stoichiometries</article-title>
          <source>FEBS Lett</source>
          <year>2002</year>
          <volume>529</volume>
          <fpage>93</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-5793(02)03251-9</pub-id>
          <?supplied-pmid 12354619?>
          <pub-id pub-id-type="pmid">12354619</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SPATA5 are associated with microcephaly intellectual disability, seizures, and hearing loss</article-title>
          <source>Am J Hum Genet</source>
          <year>2015</year>
          <volume>97</volume>
          <fpage>457</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2015.07.014</pub-id>
          <?supplied-pmid 26299366?>
          <pub-id pub-id-type="pmid">26299366</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Glycine metabolism in animals and humans: implications for nutrition and health</article-title>
          <source>Amino Acids</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>463</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="doi">10.1007/s00726-013-1493-1</pub-id>
          <?supplied-pmid 23615880?>
          <pub-id pub-id-type="pmid">23615880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Penmatsa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gouaux</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Neurotransmitter and psychostimulant recognition by the dopamine transporter</article-title>
          <source>Nature</source>
          <year>2015</year>
          <volume>521</volume>
          <fpage>322</fpage>
          <lpage>327</lpage>
          <pub-id pub-id-type="doi">10.1038/nature14431</pub-id>
          <?supplied-pmid 25970245?>
          <pub-id pub-id-type="pmid">25970245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhong</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title><sc>l</sc>-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent</article-title>
          <source>Curr Opin Clin Nutr Metab Care</source>
          <year>2003</year>
          <volume>6</volume>
          <fpage>229</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="doi">10.1097/00075197-200303000-00013</pub-id>
          <?supplied-pmid 12589194?>
          <pub-id pub-id-type="pmid">12589194</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>